ORENCIA 250 mg/15mL (Abatacept INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 250 mg/15mL

Abatacept works by binding to CD80/CD86 receptors on antigen-presenting cells, blocking the CD28-mediated T-cell activation pathway. This reduces the immune response and prevents the immune system from attacking normal tissues, thereby alleviating symptoms of autoimmune and inflammatory conditions.

The dose of ORENCIA is determined by a healthcare provider based on the patient's body weight and condition. It is typically administered as an intravenous infusion once every 2 weeks for the first 3 doses, and then once every 4 weeks thereafter.

ORENCIA is classified as a pregnancy category B drug, meaning that animal studies have not shown a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if clearly needed. It is not known whether Abatacept is excreted in human milk, so caution should be exercised when using ORENCIA while breastfeeding.

To order ORENCIA from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will reply with pricing, availability, shipping, and the import paperwork.

ORENCIA is a selective T-cell costimulation modulator, which works differently from other DMARDs like methotrexate or TNF antagonists. It is used when other DMARDs have not been effective. The choice of DMARD depends on the patient's specific condition, response to previous treatments, and other factors determined by the healthcare provider.

ORENCIA should be stored at 2-8°C, refrigerated, protected from light, and not frozen or shaken. It should be handled with care, following the instructions provided by the healthcare provider or pharmacist.

ORENCIA is administered as an intravenous infusion by a healthcare professional, usually in a clinical setting such as a hospital clinic. The infusion takes approximately 30 minutes. The dose is based on the patient's body weight and is given according to a specific schedule determined by the healthcare provider.

The most serious risks associated with ORENCIA include increased risk of infections, serious infections (including opportunistic infections), hypersensitivity reactions, gastrointestinal perforations, and blood disorders. Patients should be monitored closely for signs of these complications.

ORENCIA should not be used by patients with known hypersensitivity to Abatacept or any of its components. It should be used with caution in patients with chronic obstructive pulmonary disease, as it may increase the risk of COPD exacerbations. Patients with active infections should not use ORENCIA until the infection is controlled.